Category Archives: Global News Feed

- Single Trial to be Conducted in Patients with Fragile X Syndrome to Confirm Positive Results Seen in the Population of Responders in the CONNECT-FX Trial -

View original post here:
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome

BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.

More here:
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report

GSK will have exclusive rights to develop and commercialize SRF813, a novel antibody targeting PVRIG

Follow this link:
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program

BURLINGAME, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (NASDAQ: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: NBI). ALX’s addition to the NBI will become effective prior to market open on Monday, December 21, 2020.

See more here:
ALX Oncology Added to the NASDAQ Biotechnology Index

QuantuMDx embarks on £11 million scale-up to mass manufacture its diagnostic Q-POCTM device and disposable test cassette

Excerpt from:
QuantuMDx embarks on £11 million scale-up to mass manufacture its diagnostic Q-POCTM device and disposable test cassette

Company Anticipates NDA Resubmission in February 2021 Company Anticipates NDA Resubmission in February 2021

Read the rest here:
Avenue Therapeutics Provides Regulatory Update for IV Tramadol

Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021 Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021

Originally posted here:
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I

SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced positive top-line results from the Phase 1/2 clinical trial of OTO-413 in subjects with speech-in-noise hearing difficulty. The randomized, double-blind, placebo-controlled trial demonstrated that a single intratympanic injection of OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor (BDNF), was well-tolerated across all dose cohorts. Furthermore, there was demonstration of therapeutic activity of OTO-413 versus placebo across multiple clinically-validated speech-in-noise hearing tests at consecutive time points (Days 57 and 85). Based on these results, the company plans to continue development of OTO-413 for the treatment of hearing loss.

More here:
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss

Company obtains exclusive rights to develop and commercialize antibody therapeutics targeting insulin-like growth factor-1 receptor (IGF-1R) using Xencor’s Xtend™ half-life extension technology

More:
miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease

Company to present corporate update and plans for 2021

Read more:
BioXcel Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference